arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Annexon, Inc.

ANNX Health Care Biotechnology: Pharmaceutical Preparations
$3.75
▼ -2.9% Today
as of Oct 23, 16:45 ET
Last 30 days -5.06% Sep 14 → Oct 23
$3.34 $3.58 $3.82 $4.06 $4.30 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$3.78
High
$3.83
Low
$3.64
Volume
$3M
Avg Vol
$3M
Mkt Cap
$781M
P/E (TTM)
—
Beta
—
52w High
$7.18
52w Low
$2.54
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 4 items

Oct 16 · 21:34 PR GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Sep 24 · 12:00 PR GlobeNewswire
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Sep 16 · 20:05 PR GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
▸ Show all 4 press releases & news Free account →

ANNX earnings at a glance

The options market is pricing a move of about ±22.7% after the report, a range of roughly $2.90 to $4.60 from today's $3.75. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±6.9% on average; after the most recent report on May 7, 2026 it moved -3.2%. That means options currently expect more movement than ANNX has typically delivered. ANNX beat the consensus EPS estimate in 2 of its last 4 reported quarters. Implied volatility is currently 145%. The share price of $3.75 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$2.54
$7.18
26% of range
Avg surprise (last 4)
-0.8%
Avg reaction (last 2)
+3.7%
50% positive
Latest IV / EM
145%
EM ±22.7% · $4 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.52$-0.44$-0.36$-0.29$-0.21 Actual $-0.52Actual $-0.47Actual $-0.43Actual $-0.21Actual $-0.23Actual $-0.25Actual $-0.37Est $-0.30Actual $-0.34Est $-0.36Actual $-0.37Est $-0.34Actual $-0.23Est $-0.30Actual $-0.28 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-55M$-51M$-46M$-41M$-37M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.28 — — — — financials
Thu May 7, 2026Mar/2026 $-0.23 $-0.30 +23.3% +37.8% -3.2% earnings
Mon Nov 10, 2025Sep/2025 $-0.37 $-0.34 -8.8% — — earnings
Thu Aug 14, 2025Jun/2025 $-0.34 $-0.36 +5.6% — — earnings
Mon May 12, 2025Mar/2025 $-0.37 $-0.30 -23.3% — +10.6% earnings
Mon Sep 30, 2024Sep 2024 $-0.25 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.23 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.21 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.43 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.47 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.52 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-57M$-46M—$-57M$-52M$-57M—$-39M
Net income$-55M$-44M—$-55M$-49M$-54M—$-35M
EPS (diluted)$-0.28$-0.23—$-0.37$-0.34$-0.37—$-0.25

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$199M$175M$162M$139M$132M$97M$49M$80M
Inventory————————
Total current assets$213M$228M$242M$193M$231M$268M$316M$344M
Total assets$246M$263M$278M$229M$265M$303M$350M$379M
Long-term debt————————
Total liabilities$60M$58M$66M$68M$66M$59M$57M$47M
Total equity$186M$205M$212M$161M$199M$244M$293M$332M

Implied volatility — last 90 days

29%203%378%552%726% Jun 11 — IV 77% · EM ±8.5%Jun 15 — IV 149% · EM ±10.8%Jun 19 — IV 97% · EM ±21.4%Jun 22 — IV 90% · EM ±18.8%Jun 23 — IV 118% · EM ±24.2%Jun 25 — IV 109% · EM ±21.4%Jun 26 — IV 109% · EM ±20.8%Jun 29 — IV 114% · EM ±20.2%Jun 30 — IV 41% · EM ±7.0%Jul 01 — IV 54% · EM ±9.0%Jul 06 — IV 66% · EM ±9.2%Jul 07 — IV 147% · EM ±19.4%Jul 08 — IV 54% · EM ±6.7%Jul 09 — IV 727% · EM ±85.9%Jul 10 — IV 55% · EM ±6.0%Jul 15 — IV 302% · EM ±17.8%Jul 16 — IV 411% · EM ±17.2%Jul 20 — IV 122% · EM ±28.7%Jul 21 — IV 170% · EM ±39.4%Jul 22 — IV 50% · EM ±11.5%Jul 23 — IV 49% · EM ±11.0%Jul 24 — IV 173% · EM ±38.3%Jul 29 — IV 87% · EM ±17.5%Jul 30 — IV 82% · EM ±16.1%Aug 03 — IV 177% · EM ±31.4%Aug 06 — IV 50% · EM ±8.0%Aug 07 — IV 30% · EM ±4.6%Aug 10 — IV 188% · EM ±26.0%Aug 11 — IV 35% · EM ±4.7%Aug 12 — IV 157% · EM ±19.7%Aug 13 — IV 145% · EM ±17.1%Aug 24 — IV 90% · EM ±18.8%Aug 25 — IV 109% · EM ±22.3%Aug 26 — IV 90% · EM ±18.0%Aug 27 — IV 107% · EM ±21.0%Aug 28 — IV 121% · EM ±23.1%Aug 31 — IV 86% · EM ±15.2%Sep 01 — IV 89% · EM ±15.3%Sep 02 — IV 91% · EM ±15.2%Sep 04 — IV 118% · EM ±18.5%Sep 07 — IV 133% · EM ±18.5%Sep 14 — IV 121% · EM ±10.1%Sep 21 — IV 352% · EM ±73.5%Sep 22 — IV 158% · EM ±32.3%Sep 23 — IV 135% · EM ±27.1%Sep 24 — IV 107% · EM ±21.1%Sep 29 — IV 84% · EM ±14.5%Oct 01 — IV 165% · EM ±26.7%Oct 02 — IV 145% · EM ±22.7%

Sector peers

LXRX
Lexicon Pharmaceuticals, Inc.
$783M $1.42-9.0%
WVE
Wave Life Sciences, Inc.
$765M $3.18-5.6%
ESPR
Esperion Therapeutics, Inc.
$819M $3.18
DSGN
Design Therapeutics, Inc.
$732M $10.24-4.6%
HELP
Helus Pharma Inc.
$870M $10.19-5.5%
CRVS
Corvus Pharmaceuticals, Inc.
$876M $10.53+4.8%

ANNX earnings FAQ

What is ANNX's expected move for earnings?

Options currently price a move of about ±22.7%, or $0.85 per share either way from $3.75.

How does ANNX stock usually react to earnings?

Across the last 2 reports the average next-day move was ±6.9%, up 1 times and down 1 times.

What is ANNX's implied volatility?

ANNX's at-the-money implied volatility is about 145% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in